ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Low-Fat Abiraterone Food Effect Is of Little Consequence.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.British journal of cancer · 2025Article
- The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care.Current oncology (Toronto, Ont.) · 2024Article
- Dose optimization during drug development: whether and when to optimize.Journal of the National Cancer Institute · 2023Article
- Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer.BJUI compass · 2022Review
- Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel.Therapeutic advances in medical oncology · 2021Review
- AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.The oncologist · 2020Article
Corrections and comments
- Commented on by
- Commented on by
- Comment on
- Erratum issuedErrata.2018
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29590006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.